<DOC>
	<DOCNO>NCT02021292</DOCNO>
	<brief_summary>Study evaluate macitentan efficient , safe tolerable enough used treatment inoperable chronic thromboembolic pulmonary hypertension ( CTEPH ) .</brief_summary>
	<brief_title>Clinical Study Assess Efficacy , Safety Tolerability Macitentan Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Macitentan</mesh_term>
	<criteria>Written inform consent Subject CTEPH ( WHO Group 4 ) judge inoperable due localization obstruction surgically inaccessible ( i.e. , distal disease ) . Female childbearing potential must negative pretreatment serum pregnancy test , advise appropriate method contraception , agree use 2 reliable method contraception . Previous pulmonary endarterectomy . Recurrent thromboembolism despite sufficient oral anticoagulant . Symptomatic acute pulmonary embolism 6month period prior randomization . Known moderatetosevere restrictive lung disease ( i.e. , TLC &lt; 60 % predict value ) obstructive lung disease ( i.e. , FEV1 &lt; 70 % predict , FEV1/FVC &lt; 65 % ) know significant chronic lung disease diagnose chest imaging ( e.g. , interstitial lung disease , emphysema ) . Acute chronic condition ( dyspnea ) limit ability comply study requirement 3month period prior Screening visit Screening period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Chronic thromboembolic pulmonary hypertension ( CTEPH )</keyword>
</DOC>